Author's posts
Public Opinion Is Unified on Lowering Prescription Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
Analysis: A Procedure That Cost $1,775 in New York Was $350 in Maryland. Here’s Why.
The state’s unique health system controls what hospitals can charge for services.
The Checkup Is in the Mail? Soliciting Letter Carriers to Help Deliver Health Care
Here’s an out-of-the-box idea: Have letter carriers spend less time delivering mail and take time to perform home visits and basic health checks on the growing population of frail and elderly.
Analysis: Necessary or Not, Covid Booster Shots Are Probably on the Horizon
In today’s pharmaceutical universe, a simple “safe and effective” determination by the Food and Drug Administration to approve a drug can be manipulated to sell products of questionable value. And drugmakers can profit handsomely,
Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
Analysis: Why We’ll Likely Never Know Whether a Covid Lab Leak Happened in China
If international scientific sleuths are hoping to see a lab log or find a whistleblower, that sort of information won’t be revealed. In China today, it is dangerous to say what you know if it challenges the official government narrative.
Telemedicine Is a Tool — Not a Replacement for Your Doctor’s Touch
The pandemic has demonstrated that virtual medicine is great for simple visits. But many new types of telemedicine promoted by start-ups more clearly benefit providers’ and investors’ pockets, rather than yielding more convenient, high-quality and cost-effective medicine for patients.
Analysis: I Was a Teenage Rifle Owner, Then an ER Doctor. Assault Weapons Shouldn’t Count as ‘Guns.’
The United States has undergone a cultural, definitional, practical shift on guns and what they are for.
Analysis: How the US Invested in the War on Terrorism at the Cost of Public Health
After 9/11, as our defenses against international and bioterrorism hardened, our defenses against infectious diseases shrank. By the time a deadly virus arrived on our shores last year, nearly two-thirds of Americans were living in counties that spend more than twice as much on policing as they spend on public health.
Analysis: The Trump Health Care Policies That Deserve to Stick Around
President Joe Biden may want to continue the previous administration’s efforts to lower drug prices and make medical costs transparent.
